Company Filing History:
Years Active: 2023
Title: **The Innovations of Patricia Anderson in Pulmonary Disease Treatment**
Introduction
Patricia Anderson, a groundbreaking inventor based in Brampton, Canada, has made significant strides in the field of pharmaceutical innovations. With a focus on addressing pulmonary non-tuberculosis mycobacterial infections, her work is pivotal in advancing treatment options for patients suffering from these complex infections. Anderson's dedication to improving healthcare outcomes is exemplified by her patented invention, which combines multiple antibiotics into a single therapeutic regimen.
Latest Patents
Anderson holds one patent titled "Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections." This innovative patent involves a fixed-dose combination drug product designed for oral delivery, which includes a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine, and a fixed 40.0 mg dose of rifabutin. The product is tailored for treating pulmonary Mycobacterium avium complex (MAC) disease, providing an effective solution for individuals suffering from this condition. The patent outlines a treatment method consisting of administering the drug combination twice daily to ensure optimal therapeutic effects.
Career Highlights
Patricia Anderson is associated with Redhill Biopharma Ltd., where her expertise is instrumental in pioneering innovative treatments for infectious diseases. Her work demonstrates a commitment to translating research into actionable therapeutic strategies that cater to patient needs, highlighting her significant role in the biopharmaceutical industry.
Collaborations
Throughout her career, Anderson has collaborated with notable colleagues such as Reza Fathi and Gilead Raday. These partnerships underscore her ability to work within a team of skilled professionals, leveraging collective expertise to enhance research and development efforts in the field of infectious disease treatment.
Conclusion
Patricia Anderson's contributions to the pharmaceutical landscape exemplify the impact of innovation on patient care in treating pulmonary non-tuberculosis mycobacterial infections. Through her patented work and collaboration with industry experts, Anderson continues to pave the way for advancements in medical science while showcasing the importance of effective drug combinations in combating complex diseases. Her determination and contributions make her a noteworthy figure in the realm of medical inventions and innovations.